- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: E7389 | ER 086526 | Halaven® | NSC-707389
eribulin is an approved drug (FDA (2010), EMA (2011))
Compound class: Synthetic organic
Comment: A pan tubulin inhibitor which is a fully synthetic macrocyclic ketone analogue of the marine sponge natural product halichondrin B (a mitosis inhibitor). Marketed formulations may contain eribulin mesylate (PubChem CID 17755248).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: eribulin
|No information available.|
|Summary of Clinical Use|
|An anticancer drug approved to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline- and taxane-based chemotherapies.
Following FDA orphan drug designation and priority review, the FDA expanded approval to include treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen in January 2016.
|Mechanism Of Action and Pharmacodynamic Effects|
|A microtubule inhibitor isolated from the marine sponge Halichondria okadai.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)